Results 1 to 10 of about 44,894 (310)
Clinical and Translational Science, 2020 The cytochrome P450 2D6 (CYP2D6) gene locus is challenging to accurately genotype due to numerous single nucleotide variants and complex structural variation.
Rachel Dalton +17 more
doaj +4 more sources
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine
Expert Opinion on Drug Metabolism and Toxicology, 2022 Introduction CYP2D6 contributes to the metabolism of approximately 20–25% of drugs. However, CYP2D6 is highly polymorphic and different alleles can lead to impacts ranging from null to increase in activity.
Julie Johnson
exaly +2 more sources
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Genes, 2020 Cytochrome P450 2D6 (CYP2D6) is a critical pharmacogene involved in the metabolism of ~20% of commonly used drugs across a broad spectrum of medical disciplines including psychiatry, pain management, oncology and cardiology.
Vincent Yip +2 more
exaly +2 more sources
Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
Pharmacogenomics and Personalized Medicine, 2020 Guilherme S Lopes,1,2 Suzette J Bielinski,2 Ann M Moyer,3 John Logan Black III,3 Debra J Jacobson,1 Ruoxiang Jiang,1 Nicholas B Larson,1 Jennifer L St Sauver2 1Division of Biomedical Statistics and Informatics, Department of Health Sciences Research ...
Lopes GS +7 more
doaj +2 more sources
Clinical and Translational Science, 2020 Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and ...
Kelly E. Caudle +11 more
doaj +2 more sources
PharmVar GeneReview: CYP2D6 [PDF]
Clinical Pharmacology & Therapeutics, 2019 The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism of numerous drugs and, thus, can impact drug efficacy and safety.
C. Nofziger +12 more
semanticscholar +3 more sources
Development of a CYP2D6-enhanced HepaRG cell model with improved CYP2D6 metabolic capacity.
PLoS ONEDrug-induced liver injury is a major concern in drug development, and the limitations of animal models have driven interest in human-derived in vitro models for toxicity assessment.
Chizuka Obara +5 more
doaj +3 more sources
Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations [PDF]
Pharmacia, 2021 Wild type genotypes (CYP2D6) and their allelic variants have been described in a sample of a Peruvian mestizo population. The global allele frequency was 0.015 for CYP2D6*3 and 0.051 for CYP2D6*4. The percentages of genotypes described were 97% CYP2D6*1/*
Angel T. Alvarado +10 more
doaj +3 more sources
Clinical pharmacology and therapy, 2023 Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake inhibitors (SSRIs; i.e., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), serotonin and norepinephrine reuptake inhibitors (i.e ...
C. Bousman +17 more
semanticscholar +1 more source
Clinical pharmacology and therapy, 2021 Opioids are mainly used to treat both acute and chronic pain. Several opioids are metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone, oxycodone, and methadone).
Kristine R. Crews +20 more
semanticscholar +1 more source